安罗替尼联合TP化疗治疗晚期卵巢癌的疗效观察及对肿瘤干细胞标志物表达的影响

Effect of antirotinib combined with TP chemotherapy on advanced ovarian cancer and its effect on expression of tumor stem cell markers

目的研究安罗替尼联合TP化疗治疗晚期卵巢癌的疗效观察及对肿瘤干细胞标志物表达的影响。方法纳入驻马店市中心医院2020年9月—2022年9月收治的148例晚期卵巢癌患者,按照随机数字表法将患者分为对照组(n=74)、研究组(n=74)。对照组采用TP化疗方案治疗,研究组在对照组基础上加用安罗替尼治疗。比较两组临床疗效、治疗前后卡氏功能状态量表(KPS)、生活质量核心量表(QLQ-C30)评分、免疫功能指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、NK)、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原199(CA199)、分化抗原簇蛋白133(CD133)、DEAD家族多肽4(DDX4)]水平、血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、凋亡蛋白酶激活因子(Apaf-1)、趋化因子配体18(CCL18)水平、不良反应。结果研究组临床总有效率79.73%(59/74)高于对照组64.86%(48/74)(P<0.05);治疗3个周期后研究组KPS评分高于对照组,QLQ-C30评分低于对照组(P<0.05);治疗3个周期后研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、NK水平低于对照组(P<0.05);治疗3个周期后研究组血清CEA、CA199、CD133、DDX4水平低于对照组(P<0.05);治疗3个周期后研究组血清TNF-α、IL-1β、CCL18水平低于对照组,Apaf-1水平高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论安罗替尼联合TP化疗治疗晚期卵巢癌患者疗效显著,可有效缓解临床症状,减少对机体免疫功能的影响,调节血清肿瘤标志物水平,促进病情恢复,且安全可控。

Objective To investigate the efficacy of antirotinib combined with TP chemotherapy in the treatment of ad⁃vanced ovarian cancer and its effect on the expression of tumor stem cell markers.Methods Totally 148 patients with advanced ovarian cancer admitted to our hospital(from September 2020 to September 2022)were divided into control group(n=74)and study group(n=74)according to random number table.The control group was treated with TP chemotherapy,and the study group was treated with anrotinib on the basis of the control group.Clinical efficacy,Cassini functional status Scale(KPS),Core Quality of Life Scale(QLQ-C30)scores before and after treatment,immune function indexes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+),NK),serum tumor markers[CEA],carbohydrate antigen 199(CA199)and differentiation antigen cluster protein 13 were compared between the two groups 3(CD133),DEAD fami⁃ly polypeptide 4(DDX4)]levels,serum tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β)levels,ap⁃optotic protease activator(Apaf-1),chemokine ligand 18(CCL18)levels,toxicity and side effects.Results The to⁃tal effective rate of the study group was 79.73%(59/74)higher than that of the control group 64.86%(48/74)(P<0.05).After 3 cycles of treatment,the KPS score of the study group was higher than that of the control group,and the QLQ-C30 score of the study group was lower than that of the control group(P<0.05).After 3 cycles of treat⁃ment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and NK in the study group were lower than those in the control group(P<0.05).The levels of CEA,CA199,CD133 and DDX4 in the study group were lower than those in the control group after 3 cycles of treatment(P<0.05).After 3 cycles of treatment,the levels of TNF-α,IL-1βand CCL18 in the study group were lower than those in the control group,while the levels of Apaf-1 were higher than those in the control group(P<0.05).There was no significant difference in the incidence of toxicity and side effects between the two groups(P>0.05).Conclusion Androtinib combined with TP chemotherapy is effective in the treatment of ad⁃vanced ovarian cancer patients,which can effectively relieve clinical symptoms,reduce the impact on immune function,regulate the level of serum tumor markers,promote disease recovery,and is safe and controllable.